Lantheus Holdings (LNTH) has been drawing attention after its shares last closed at US$101. The stock is higher compared with this time last year, although it has moved lower over the past month.

For Lantheus Holdings, the 1 day share price return of 1% comes after a 30 day share price return that is down 9%, while the year to date share price return of 50.14% and 1 year total shareholder return of 41.87% point to momentum that has largely been positive over a longer stretch.

If this kind of move has you looking beyond a single stock, it could be a good moment to scan other healthcare related opportunities using our screener for 41 healthcare AI stocks

Lantheus Holdings has cooled off after a strong year, and the recent pullback raises a simple question. Is the meaningful upside still ahead at around US$101, or has most of the opportunity already played out on the current valuation?

Most Popular Narrative: 3% Undervalued

The most followed narrative currently places Lantheus Holdings’ fair value at about $104 per share, slightly above the last close at $101, and anchors that view on how its radiodiagnostic pipeline and earnings profile could evolve from here.

Multiple new product launches within the next 18 months including the new F 18 PSMA PET, MK-6240, OCTEVY, and PNT2003 are set to diversify the revenue base, mitigate concentration risk, and open additional growth channels in oncology and neuroendocrine tumor imaging, supporting both top-line and future earnings expansion.

Want to see what kind of revenue mix and profit margins sit behind that fair value for Lantheus Holdings? The narrative leans on a specific growth pace, a higher earnings base, and a lower future earnings multiple than today. The full breakdown shows how those ingredients fit together to justify the current estimate.

Result: Fair Value of $104.08 (UNDERVALUED)

However, the Lantheus Holdings story also carries clear risks, including pressure on PYLARIFY pricing and reimbursement, as well as uncertainty around how acquisitions and new launches translate into earnings.

Next Steps

This mix of optimism and concern around Lantheus Holdings is clear, so take a closer look at the full picture now and weigh it up for yourself using the 4 key rewards and 1 important warning sign

Looking for more ideas beyond Lantheus Holdings?

Do not stop with just Lantheus Holdings. Use this moment to broaden your watchlist with other carefully filtered opportunities before they move without you.

• Spot opportunities that combine quality and attractive pricing by checking the 57 high quality undervalued stocks.
• Prioritize stability and capital protection first by reviewing the 89 resilient stocks with low risk scores.
• Hunt for underfollowed opportunities with strong fundamentals through the screener containing 20 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.